View More View Less
  • 1 Department of Microbiology, Faculty of Medicine, Jagiellonian University Collegium Medicum, Kraków, , Poland
  • | 2 Biophage Pharma SA, Kraków, , Poland
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $784.00

Clostridioides (formerly Clostridium) difficile infections (CDIs) are becoming more common and more serious. C. difficile is the etiologic agent of antibiotic-associated diarrhea, pseudomembranous enterocolitis, and toxic megacolon while CDIs recur in 7.9% of patients. About 42.9 CDI cases/10,000 patient-days are diagnosed each day in Europe, whereas in Poland 5.6 CDI cases/10,000 patient-days are reported; however, the median for European countries is 2.9 CDI cases/10,000 patient-days. Epidemiology of CDIs has changed in recent years and risk of developing the disease has doubled in the past decade that is largely determined by use of antibiotics. Studies show that rate of antibiotic consumption in the non-hospital sector in Poland is much higher than the European average (27 vs. 21.8 DDD/1,000 patient-days), and this value has increased in recent years. Antibiotic consumption has also increased in the hospital sector, especially in the intensive care units – 1,520 DDD/1,000 patient-days (ranging from 620 to 3,960 DDD/1,000 patient-days) – and was significantly higher than in Germany 1,305 (ranging from 463 to 2,216 DDD/1,000 patient-days) or in Sweden 1,147 (ranging from 605 to 2,134 DDD/1,000 patient-days). The recent rise in CDI incidence has prompted a search for alternative treatments. Great hope is placed in probiotics, bacteriocins, monoclonal antibodies, bacteriophages, and developing new vaccines.

  • 1.

    Murphy, C., Veron, M., Cullen, M.: Intravenous immunoglobulin for resistant Clostridium difficile infection. Age Ageing 35, 8586 (2006).

  • 2.

    Hall, I. C., O’Toole, E.: Intestinal flora in newborn infants with a description of a new pathogenic anaerobe, Bacilus difficilis. Am J Dis Child 49, 390402 (1935).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Aslam, S., Hamill, R. J., Musher, D. M.: Treatment of Clostridium difficile-associated disease: Old therapies and new strategies. Lancet Infect Dis 5, 549557 (2005).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Pituch, H., Albrecht, P.: Clostridium difficile – narastający problem diagnostyczny i terapeutyczny [Clostridium difficile – A growing diagnostic and therapeutic problem]. Gastroenterol Klin 5, 4051 (2013).

    • Search Google Scholar
    • Export Citation
  • 5.

    Zanella Terrier, M. C., Simonet, M. L., Bichard, P., Frossard, J. L.: Recurrent Clostridium difficile infections: The importance of the intestinal microbiota. World J Gastroenterol 20, 74167423 (2014).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Kelly, C. P.: Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 18, 2127 (2012).

  • 7.

    European Centre for Disease Prevention and Control. Clostridium difficile Infections Annual Epidemiological Report for 2016. ECDC, Stockholm, 2018. Available at https://ecdc.europa.eu/sites/portal/files/documents/AER_for_2016-C-difficile_0.pdf

    • Search Google Scholar
    • Export Citation
  • 8.

    Naaber, P., Smidt, I., Stsepetova, J., Brilene, T., Annuk, H., Mikelsaar, M.: Inhibition of Clostridium difficile strains by in intestinal Lactobacillus species. J Med Microbiol 53, 551554 (2004).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Deshpande, A., Pasupuleti, V., Thota, P., Pant, C., Rolston, D. D., Sferra, T. J., Hernandez, A. V., Donskey, C. J.: Community-associated Clostridium difficile infection and antibiotics: A meta-analysis. J Antimicrob Chemother 68, 19511961 (2013).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Jenberg, C., Löfmark, S., Edlund, C., Jansson, J. K.: Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J 1, 5666 (2007).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Furuya-Kanamori, L., Stone, J. C., Clark, J., McKenzie, S. J., Yakob, L., Paterson, D. L., Riley, T. V., Doi, S. A., Clements, A. C.: Comorbidities, exposure to medications, and the risk of community-acquired Clostridium difficile infection: A systematic review and meta-analysis. Infect Control Hosp Epidemiol 36, 13241 (2015).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., Loo, V., Sammons, J. S., Sandora, T. J., Wilcox, M. H.: Clinical practice guidelines for Clostridium difficile infections in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 66, e1e48 (2018).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Lucado, J., Gould, C., Elixhauser, A.: Clostridium difficile Infections (CDI) in Hospital Stays, 2009: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD: Agency for Health Care Policy and Research (US), 2012. Available at https://www.ncbi.nlm.nih.gov/books/NBK92613/

    • Search Google Scholar
    • Export Citation
  • 14.

    Centers for Disease Control and Prevention (CDC): Severe Clostridium difficile-associated disease in populations previously at low risk: Four states, 2005. Morb Mortal Wkly Rep 54, 12011205 (2005).

    • Search Google Scholar
    • Export Citation
  • 15.

    Lessa, C. F., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, I. J., Phipps, C. E., Wilson, E. L., Winston, G. L., Cohen, A. J., Limbago, M. B., Fridkin, K. S., Gerding, N. D., Clifford, L., McDonald, C. L.: Burden of Clostridium difficile infection in the United States. N Engl J Med 372, 825834 (2015).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Pituch, H., Obuch-Woszczatyński, P., Lachowicz, D., Kuthan, R., Dzierżanowska-Fangrat, K., Mikucka, A., Jermakow, K., Pituch-Zdanowska, A., Davies, K.: Prevalence of Clostridium difficile infection in hospitalized patients with diarrhoea: Results of a Polish multicenter, prospective, biannual point-prevalence study. Adv Med Sci 63, 290295 (2018).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Kołpa, M., Wałaszek, M., Różańska, A., Wolak, Z., Wójkowska-Mach, J.: Hospital-wide surveillance of healthcare-associated infections as a source of information about specific hospital needs. A 5-year observation in a multiprofile provincial hospital in the south of Poland. Int J Environ Res Public Health 15, E1956 (2018).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Ziółkowski, G., Pawłowska, I., Krawczyk, L., Wójkowska-Mach, J.: Antibiotic consumption versus the prevalence of multidrug-resistant Acinetobacter baumannii and Clostridium difficile infections at an ICU from 2014–2015. J Infect Public Health 11, 626630 (2018).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Pituch, H., Obuch-Woszczatyński, P., Lachowicz, D., Wultańska, D., Karpiński, P., Młynarczyk, G., van Dorp, S. M., Kuijper, E. J.: Polish Clostridium difficile study group: hospital-based Clostridium difficile infection surveillance reveals high proportions of PCR ribotypes 027 and 176 in different areas of Poland, 2011 to 2013. Euro Surveill 20, 38 (2015).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Pituch, H., Bakker, D., Kuijper, E., Obuch-Woszczatyński, P., Wultańska, D., Nurzyńska, G., Bielec, A., Bar-Andziak, E., Łuczak, M.: First isolation of Clostridium difficile PCR-ribotype 027/toxinotype III in Poland. Pol J Microbiol 57, 267268 (2008).

    • Search Google Scholar
    • Export Citation
  • 21.

    Pituch, H., Obuch-Woszczatyński, P., Lachowicz, D., Wultańska, D., Karpiński, P., Młynarczyk, G., van Dorp, S. M., Kuijper, E. J.: Hospital-based Clostridium difficile infection surveillance reveals high proportions of PCR ribotypes 027 and 176 in different areas of Poland, 2011 to 2013. Euro Surveill 20, 38 (2015).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22.

    Aptekorz, M., Szczegielniak, A., Wiechuła, B., Harmanus, C., Kuijper, E., Martirosian, G.: Occurrence of Clostridium difficile ribotype 027 in hospitals of Silesia, Poland. Anaerobe 45, 106113 (2017).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    Czepiel, J., Kędzierska, J., Biesiada, G., Birczyńska, M., Perucki, W., Nowak, P., Garlicki, A.: Epidemiology of Clostridium difficile infection: Results of a hospital-based study in Krakow, Poland. Epidemiol Infect 143, 32353243 (2015).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24.

    Barlam, T. F., Cosgrove, S. E., Abbo, L. M., MacDougall, C., Schuetz, A. N., Septimus, E. J., Srinivasan, A., Dellit, T. H., Falck-Ytter, Y. T., Fishman, N. O., Hamilton, C. W., Jenkins, T. C., Lipsett, P. A., Malani, P. N., May, L. S., Moran, G. J., Neuhauser, M. M., Newland, J. G., Ohl, C. A., Samore, M. H., Seo, S. K., Trivedi, K. K.: Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 62, 5177 (2016).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25.

    Wojkowska-Mach, J., Godman, B., Glassman, A., Kurdi, A., Pilc, A., Rozanska, A., Skoczyński, S., Wałaszek, M., Bochenek, T.: Antibiotic consumption and antimicrobial resistance in Poland; findings and implications. Antimicrob Resist Infect Control 7, 136 (2018).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26.

    Hanberger, H., Erlandsson, M., Burman, L. G., Cars, O., Gill, H., Lindgren, S., Nilsson, L. E., Olsson-Liljequist, B., Walther, S.: High antibiotic susceptibility among bacterial pathogens in Swedish ICUs. Report from a nationwide surveillance program using TA90 as a novel index of susceptibility. Scand J Infect Dis 36, 2430 (2004).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27.

    Meyer, E., Gastmeier, P., Deja, M., Schwab, F.: Antibiotic consumption and resistance: data from Europe and Germany. Int J Med Microbiol 303, 388395 (2013).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28.

    Trejnowska, E., Deptuła, A., Tarczyńska-Słomian, M., Knapik, P., Jankowski, M., Misiewska-Kaczur, A., Tamowicz, B., Śmiechowicz, J., Antończyk, R., Armatowicz, P., Sułkowski, W., Durek, G.: Surveillance of antibiotic prescribing in intensive care units in Poland. Can J Infect Dis Med Microbiol 2018, 5670238 (2018).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29.

    European Centre for Disease Prevention and Control. Antimicrobial Consumption: Annual Epidemiological Report for 2017. ECDC, Stockholm, 2018. Available at https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2017-antimicrobial-consumption.pdf

    • Search Google Scholar
    • Export Citation
  • 30.

    Lachowicz, D., Pituch, H., Obuch-Woszczatyński, P.: Antimicrobial susceptibility patterns of Clostridium difficile strains belonging to different polymerase chain reaction ribotypes isolated in Poland in 2012. Anaerobe 31, 3741 (2015).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31.

    Barker, A. K., Ngam, C., Musuuza, J. S., Vaughn, V. M., Safdar, N.: Reducing Clostridium difficile in the inpatient settings: a systematic review of the adherence to and effectivness of C. difficile prevention bundles. Infect Control Hosp Epidemiol 38, 639650 (2017).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32.

    Tasteyre, A., Karjalainen, T., Avesani, V., Delmée, M., Collignon, A., Bourlioux, P., Barc, M. C.: Phenotypic and genotypic diversity of the flagellin gene (fliC) among Clostridium difficile isolates from different serogroups. J Clin Microbiol 38, 31793186 (2000).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33.

    Hennequin, C., Porcheray, F., Waligora-Dupriet, A., Collignon, A., Barc, M., Bourlioux, P., Karjalainen, T.: GroEL (Hsp60) of Clostridium difficile is involved in cell adherence. Microbiology 147, 8796 (2001).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 34.

    Waligora, A. J., Hennequin, C., Mullany, P., Bourlioux, P., Collignon, A., Karjalainen, T.: Characterization of a cell surface protein of Clostridium difficile with adhesive properties. Infect Immun 69, 21442153 (2001).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35.

    Hennequin, C., Janoir, C., Barc, M. C., Collignon, A., Karjalainen, T.: Identification and characterization of a fibronectin-binding protein from Clostridium difficile. Microbiology 149, 27792787 (2003).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36.

    Kirby, J. M., Ahern, H., Roberts, A. K., Kumar, V., Freeman, Z., Acharya, K. R., Shone, C. C.: Cwp84, a surface-associated cysteine protease, plays a role in the maturation of the surface layer of Clostridium difficile. J Biol Chem 284, 3466634673 (2009).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 37.

    Semenyuk, E. G., Laning, M. L., Foley, J.: Spore formation and toxin production in Clostridium difficile biofilms. PLoS One 9, 87757 (2014).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 38.

    Burdon, D. W., George, R. H., Mogg, G. A., Arabi, Y., Thompson, H., Johnson, M., Alexander-Williams, J., Keighley, M. R.: Faecal toxin and severity of antibiotic-associated pseudomembranous colitis. J Clin Pathol 34, 548551 (1981).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 39.

    Kuehne, S. A., Cartman, S. T., Heap, J. T., Kelly, M. L., Cockayne, A., Minton, N. P.: The role of toxin A and toxin B in Clostridium difficile infection. Nature 467, 711712 (2010).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 40.

    Pituch, H., Kreft, D., Obuch-Woszczatynski, P., Wultańska, D., Meisel-Mikołajczyk, F., Łuczak, M., van Belkum, A.: Clonal spread of a Clostridium difficile strain with a complete set of a toxin A, toxin B, and a binary toxin genes among Polish patients with Clostridium difficile associated diarrhea. J Clin Microbiol 43, 772775 (2005).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 41.

    Freeman, J., Fawley, W. N., Baines, S., Wilcox, M.: Measurement of toxin production by Clostridium difficile. Lancet 367, 982983 (2006).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 42.

    Castagliuolo, I., Kelly, C. P., Qiu, B. S., Nikulasson, S. T., LaMont, J. T., Pothoulakis, C.: IL-11 inhibits Clostridium difficile toxin A enterotoxicity in rat ileum. Am J Physiol 273, 333341 (1997).

    • Search Google Scholar
    • Export Citation
  • 43.

    Pothoulakis, C., LaMont, J. T.: Clostridium difficile colitis and diarrhea. Gastroenterol Clin North Am 22, 623637 (1993).

  • 44.

    Khanna, S., Baddour, L. M., Huskins, W. C., Kammer, P. P., Faubion, W. A., Zinsmeister, A. R., Harmsen, W. S., Pardi, D. S.: The epidemiology of Clostridium difficile infection in children: A population-based study. Clin Infect Dis 56, 14011406 (2013).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 45.

    Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., Zuckerbraun, B. S.: Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108, 47898 (2013).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 46.

    Zar, F. A., Bakkanagari, S. R., Moorthi, K. M., Davis, M. B.: A comparsion of vancomycin and metronidazole for treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45, 302307 (2007).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 47.

    Di, X., Bai, N., Zhang, X., Liu, B., Ni, W., Wang, J., Wang, K., Liang, B., Liu, Y., Wang, R.: A meta-analysis of metronidazole and vancomycin for the treatment Clostridium difficile infection, stratified by disease severity. Braz J Infect Dis 19, 339349 (2015).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 48.

    Gerding, D. N., Hecht, D. W., Louie, T., Nord, C. E., Talbot, G. H., Cornely, O. A., Buitrago, M., Best, E., Sambol, S., Osmolski, J. R., Kracker, H., Locher, H. H., Charef, P., Wilcox, M.: Susceptibility of Clostridium difficile isolates from a phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. J Antimicrob Chemother 71, 213219 (2015).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 49.

    Freeman, J., Vernon, J., Vickers, R., Wilcox, M. H.: Susceptibility of Clostridium difficile isolates of varying antimicrobial resistance phenotypes to SMT19969 and 11 comparators. Antimicrob Agents Chemother 60, 689692 (2015).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 50.

    Kokai-Kun, J. F., Roberts, T., Coughlin, O., Le, C., Whalen, H., Stevenson, R., Wacher, V. J., Sliman, J.: Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: A double-blind, phase 2b, randomised placebo-controlled trial. Lancet Infect Dis 19, 487496 (2019).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 51.

    Taylor, N. S., Thorne, G. M., Bartlett, J. G.: Comparison of two toxins produced by Clostridium difficile. Infect Immun 34, 10361043 (1981).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 52.

    Dabard, J., Dubos, F., Martinet, L., Ducluzeau, R.: Experimental reproduction of neonatal diarrhea in young gnotobiotic hares simultaneously associated with Clostridium difficile and other Clostridium strains. Infect Immun 24, 711 (1979).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 53.

    Triadafilopoulos, G., Pothoulakis, C., O’Brien, M. J., LaMont, J. T.: Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology 93, 273279 (1987).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 54.

    van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, EG., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F., Tijssen, J. G., Speelman, P., Dijkgraaf, M. G., Keller, J. J.: Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368, 407415 (2013).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 55.

    Borody, T. J., Connelly, N., Mitchell, S. W.: Fecal microbiota transplantation in gastrointestinal diseases. Pol Arch Med Wewn 125, 852858 (2015).

    • Search Google Scholar
    • Export Citation
  • 56.

    FAO: Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. FAO, London Ontario, Canada, 2002. Available at http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf

    • Search Google Scholar
    • Export Citation
  • 57.

    Johnson, S., Maziade, P. J., McFarland, L. V., Trick, W., Donskey, C., Currie, B., Low, D. E., Goldstein, E. J.: Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis 16, 786792 (2012).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 58.

    Castagliuolo, I., LaMont, J. T., Nikulasson, S. T., Pothoulakis, C.: Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 64, 52255232 (1996).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 59.

    Czepiel, J., Biesiada, G., Dróżdż, M., Gdula-Argasińska, J., Żurańska, J., Marchewka, J., Perucki, W., Wołkow, P., Garlicki, A.: The presence of IL-8 +781 T/C polymorphism is associated with the parameters of severe Clostridium difficile infection. Microb Pathog 114, 281285 (2018).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 60.

    Plummer, S., Weaver, M. A., Harris, J. C., Dee, P., Hunter, J.: Clostridium difficile pilot study: Effects of probiotic supplementation on the incidence of C. difficile diarrhea. Int Microbiol 7, 5962 (2004).

    • Search Google Scholar
    • Export Citation
  • 61.

    Kotowska, M., Albrecht, P., Szajewska, H.: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: A randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 21, 583590 (2005).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 62.

    Boonma, P., Spinler, J. K., Venable, S. F., Versalovic, J., Tumwasorn, S.: Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cells. BMC Microbiol 14, 177 (2014).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 63.

    Kaur, S., Vaishnavi, C., Prasad, K. K., Ray, P., Kochhar, R.: Effect of Lactobacillus acidophilus & epidermal growth factor on experimentally induced Clostridium difficile infection. Indian J Med Res 133, 434441 (2011).

    • Search Google Scholar
    • Export Citation
  • 64.

    Lee, J. S., Chung, M. J., Seo, J. G.: In vitro evaluation of antimicrobial activity of lactic acid bacteria against Clostridium difficile. Toxicol. Res. 29, 99106 (2013).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 65.

    Leclerq, R., Cantón, R., Brown, D. F., Giske, C. G., Heisig, P., MacGowan, A. P., Mouton, J. W., Nordmann, P., Rodloff, A. C., Rossolini, G. M., Soussy, C. J., Steinbakk, M., Winstanley, T. G., Kahlmeter, G.: EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19, 141160 (2013).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 66.

    Hell, M., Bernhofer, C., Stalzer, P., Kern, J. M., Claassen, E.: Probiotics in Clostridium difficile infection: Reviewing the need for a multistrain probiotic. Benef Microb 4, 3951 (2013).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 67.

    Hütt, P., Shchepetova, J., Löivukene, K., Kullisaar, T., Mikelsaar, M.: Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and uropathogens. J Appl Microbiol 100, 13241332 (2005).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 68.

    Cassone, M., Serra, P., Mondello, F., Girolamo, A., Scafetti, S., Pistella, E., Venditti, M.: Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treatment with a probiotic preparation of the organism. J Clin Microbiol 41, 53405343 (2003).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 69.

    Rea, M. C., Sit, C. S., Clayton, E., O’Connor, P. M., Whittal, R. M., Zheng, J., Vederas, J. C., Ross, R. P., Hill, C.: Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc Natl Acad Sci U S A 107, 93529357 (2010).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 70.

    Pechine, S., Gleizes, A., Janoir, C., Gorges-Kergot, R., Barc, M. C., Delmée, M., Collignon, A.: Immunological properties of surface proteins of Clostridium difficile. J Med Microbiol 54, 193196 (2005).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 71.

    Pechine, S., Janoir, C., Collignon, A.: Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile-associated disease. J Clin Microbiol 43, 50185025 (2005).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 72.

    Pechine, S., Deneve, C., Le Monnier, A., Hoys, S., Janoir, C., Collignon, A.: Immunization of hamsters against Clostridium difficile infection using the Cwp84 protease as an antigen. FEMS Immunol Med Microbiol 63, 7381 (2011).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 73.

    Wright, A., Drudy, D., Kyne, L., Brown, K., Fairweather, N. F.: Immunoreactive cell wall proteins of Clostridium difficile identified by human sera. J Med Microbiol 57, 750756 (2008).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 74.

    Wilcox, M. H., Gerding, D. N., Poxton, I. R., Kelly, C., Nathan, R., Birch, T., Cornely, A. O., Rahav, G., Bouza, E., Lee, C., Jenkin, G., Jensen, W., Kim, Y., Yoshida, J., Gabryelski, L., Pedley, A., Eves, K., Tipping, R., Guris, D., Kartsonis, N., Dorr, M.: Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med 376, 305317 (2017).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 75.

    Foglia, G., Shah, S., Luxemburger, C., Pietrobon, P. J.: Clostridium difficile: Development of a novel candidate vaccine. Vaccine 30, 43074309 (2012).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 76.

    Greenberg, R. N., Marburg, T. C., Foglia, G., Warny, M.: Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 30, 22452249 (2012).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 77.

    de Bruyn, G., Saleh, J., Workman, D., Pollak, R., Elinoff, V., Fraser, N. J., Lefebvre, G., Martens, M., Mills, R. E., Nathan, R., Trevino, M., van Cleeff, M., Foglia, G., Ozol-Godfrey, A., Patel, D. M., Pietrobon, P. J., Gesser, R.: Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trial. Vaccine 34, 21702178 (2016).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 78.

    Sekulovic, O., Meessen-Pinard, M., Fortier, L. C.: Prophage-stimulated toxin production in Clostridium difficile NAP1/027 lysogens. J Bacteriol 193, 27262734 (2011).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 79.

    Rea, M. C., Alemayehu, D., Rosss, R. P., Hill, C.: Gut solutions to a gut problem: Bacteriocins, probiotics and bacteriophage for control of Clostridium difficile infection. J Med Microbiol 62, 13691378 (2013).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 80.

    Nale, J. Y., Spencer, J., Hargreaves, K. R., Buckley, A. M., Trzepiński, P., Douce, R. G., Clokie, M. R. J.: Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in vivo. Antimicrob Agents Chemother 60, 968981 (2016).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 81.

    Nale, J. Y., Redgwell, T. A., Millard, A., Clokie, M. R. J.: Effiacy of optimised bacteriophage cocktail to clear Clostridium difficile in a batch fermentation model. Antibiotics (Basel) 7, 13 (2018).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 82.

    Tschudin-Sutter, S., Kuijper, E. J., Durovic, A., Vehreschild, M. J. G. T., Barbut, F., Eckert, C., Fitzpatrick, F., Hell, M., Norèn, T., O’Driscoll, J., Coia, J., Gastmeier, P., von Müller, L., Wilcox, M. H., Widmer, A. F.: Guidance document for prevention of Clostridium difficile infection in acute healthcare settings. Clin Microbiol Infect 24, 10511054 (2018).

    • Crossref
    • Search Google Scholar
    • Export Citation

 

The author instruction is available in PDF.
Please, download the file from HERE

Senior editors

Editor-in-Chief: Prof. Dóra Szabó (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Managing Editor: Dr. Béla Kocsis (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Co-editor: Dr. Andrea Horváth (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Editorial Board

  • Prof. Éva ÁDÁM (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Sebastian AMYES (Department of Medical Microbiology, University of Edinburgh, Edinburgh, UK.)
  • Dr. Katalin BURIÁN (Institute of Clinical Microbiology University of Szeged, Szeged, Hungary; Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary.)
  • Dr. Orsolya DOBAY (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Ildikó Rita DUNAY (Institute of Inflammation and Neurodegeneration, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany)
  • Prof. Levente EMŐDY(Department of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary.)
  • Prof. Anna ERDEI (Department of Immunology, Eötvös Loránd University, Budapest, Hungary, MTA-ELTE Immunology Research Group, Eötvös Loránd University, Budapest, Hungary.)
  • Prof. Éva Mária FENYŐ (Division of Medical Microbiology, University of Lund, Lund, Sweden)
  • Prof. László FODOR (Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Budapest, Hungary)
  • Prof. József KÓNYA (Department of Medical Microbiology, University of Debrecen, Debrecen, Hungary)
  • Prof. Yvette MÁNDI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Károly MÁRIALIGETI (Department of Microbiology, Eötvös Loránd University, Budapest, Hungary)
  • Prof. János MINÁROVITS (Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, Hungary)
  • Prof. Béla NAGY (Centre for Agricultural Research, Institute for Veterinary Medical Research, Budapest, Hungary.)
  • Prof. István NÁSZ (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Kristóf NÉKÁM (Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.)
  • Dr. Eszter OSTORHÁZI (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Rozália PUSZTAI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Peter L. RÁDY (Department of Dermatology, University of Texas, Houston, Texas, USA)
  • Prof. Éva RAJNAVÖLGYI (Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary)
  • Prof. Ferenc ROZGONYI (Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary)
  • Prof. Zsuzsanna SCHAFF (2nd Department of Pathology, Semmelweis University, Budapest, Hungary)
  • Prof. Joseph G. SINKOVICS (The Cancer Institute, St. Joseph’s Hospital, Tampa, Florida, USA)
  • Prof. Júlia SZEKERES (Department of Medical Biology, University of Pécs, Pécs, Hungary.)
  • Prof. Mária TAKÁCS (National Reference Laboratory for Viral Zoonoses, National Public Health Center, Budapest, Hungary.)
  • Prof. Edit URBÁN (Department of Medical Microbiology and Immunology University of Pécs, Pécs, Hungary; Institute of Translational Medicine, University of Pécs, Pécs, Hungary.)

 

Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary

Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu

 Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • Chemical Abstracts
  • Global Health
  • Index Medicus
  • Index Veterinarius
  • Medline
  • Referativnyi Zhurnal
  • SCOPUS
  • Science Citation Index Expanded
2020  
Total Cites 662
WoS
Journal
Impact Factor
2,048
Rank by Immunology 145/162(Q4)
Impact Factor Microbiology 118/137 (Q4)
Impact Factor 1,904
without
Journal Self Cites
5 Year 0,671
Impact Factor
Journal  0,38
Citation Indicator  
Rank by Journal  Immunology 146/174 (Q4)
Citation Indicator  Microbiology 120/142 (Q4)
Citable 42
Items
Total 40
Articles
Total 2
Reviews
Scimago 28
H-index
Scimago 0,439
Journal Rank
Scimago Immunology and Microbiology (miscellaneous) Q4
Quartile Score Medicine (miscellaneous) Q3
Scopus 438/167=2,6
Scite Score  
Scopus General Immunology and Microbiology 31/45 (Q3)
Scite Score Rank  
Scopus 0,760
SNIP
Days from  225
submission
to acceptance
Days from  118
acceptance
to publication
Acceptance 19%
Rate

2019  
Total Cites
WoS
485
Impact Factor 1,086
Impact Factor
without
Journal Self Cites
0,864
5 Year
Impact Factor
1,233
Immediacy
Index
0,286
Citable
Items
42
Total
Articles
40
Total
Reviews
2
Cited
Half-Life
5,8
Citing
Half-Life
7,7
Eigenfactor
Score
0,00059
Article Influence
Score
0,246
% Articles
in
Citable Items
95,24
Normalized
Eigenfactor
0,07317
Average
IF
Percentile
7,690
Scimago
H-index
27
Scimago
Journal Rank
0,352
Scopus
Scite Score
320/161=2
Scopus
Scite Score Rank
General Immunology and Microbiology 35/45 (Q4)
Scopus
SNIP
0,492
Acceptance
Rate
16%

 

Acta Microbiologica et Immunologica Hungarica
Publication Model Online only Hybrid
Submission Fee none
Article Processing Charge 1100 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2021 Online subsscription: 652 EUR / 812 USD
Subscription fee 2022 Online subsscription: 662 EUR / 832 USD
Print + online subscription: 740 EUR / 930 USD
Subscription Information Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Acta Microbiologica et Immunologica Hungarica
Language English
Size A4
Year of
Foundation
1954
Publication
Programme
2021 Volume 68
Volumes
per Year
1
Issues
per Year
4
Founder Magyar Tudományos Akadémia
Founder's
Address
H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1217-8950 (Print)
ISSN 1588-2640 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jun 2021 19 0 0
Jul 2021 23 4 3
Aug 2021 9 0 0
Sep 2021 17 0 0
Oct 2021 29 1 1
Nov 2021 10 0 0
Dec 2021 0 0 0